Publications by authors named "Carissa Carrier"
An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic Steatohepatitis.
J Pediatr Gastroenterol Nutr
August 2023
Article Synopsis
- - Nonalcoholic fatty liver disease is common in children, and elafibranor, a drug that activates certain receptors, is being explored as a treatment for nonalcoholic steatohepatitis (NASH) in this age group.
- - In a study, ten boys aged 8-17 were given either 80mg or 120mg of elafibranor each day for 12 weeks to evaluate drug absorption, safety, and changes in liver enzyme levels.
- - Results showed that elafibranor was well-tolerated, and the 120mg group experienced a significant reduction in alanine aminotransferase (ALT) levels, suggesting potential benefits for liver health in children with NASH.*
BACKGROUNDHepatic de novo lipogenesis (DNL) is elevated in nonalcoholic fatty liver disease (NAFLD). Improvements in hepatic fat by dietary sugar reduction may be mediated by reduced DNL, but data are limited, especially in children. We examined the effects of 8 weeks of dietary sugar restriction on hepatic DNL in adolescents with NAFLD and correlations between DNL and other metabolic outcomes.
View Article and Find Full Text PDF